WORCESTER, Mass.--(BUSINESS WIRE)--Nov. 3, 2005--Massachusetts-based company Total ReCord, Inc. plans to begin clinical trials in January 2006 on RMx(TM), its remarkable alternative to embryonic stem cells in the treatment of spinal cord injuries. Total ReCord is looking to raise capital to fund these clinical trials and further R&D into its other innovative products starting at today’s MassOpps Investment Conference in Boston, MA, where some of its key results will be unveiled for the first time in public. Other technologies in Total ReCord’s portfolio include Trans-Neural Implants(TM), neural stem cells, and SpheroGel(TM) (exclusively licensed from NeuroVita) which is currently in Phase I/II clinical trials.
